

Brigard & Castr

Abogados
AS: 97.382

Apartado 3892

Cra. 7 16-56
Bogotá - Colombia S.A.

Tel. Conm. 3802200
Tel./Fax: (57.1) 2827976
(57.1) 3802700

E.Mail:bricas@brigardycastro.com.co

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIVISION DE NUEVAS CREACIONES

E. S. D.

SUPERINTENDENCIA Y COMERCIO

Radicacion : 05/05/18 00000000

Folios: 32

Fecha (IMP): 2005-11-30 16:24:54

Procedente : 011 PCT-PATENT 3/9 FASE NUL 444 REPUESTA

Dependencia: 2005 DIVISION DE NUEVAS CREACIONES

RESPUESTA A OFICIO 00001 DE AGOSTO 05/20

REF: Expediente No. 05 058.718 - Solicitud de Patente FASE NACIONAL

Corresp. a la Solicitud Internacional PCT/US2003/040932

a favor de PHARMACIA CORPORATION

Titulada: COMPUESTOS DE PIRAZOL ACÍCLICO PARA LA INHIBICIÓN DE
PREOTEÍNA CINASA-2 ACTIVADA POR PROTEÍNA CINASA ACTIVADA POR
MITÓGENOS

JUAN PABLO CADENA SARMIENTO, vecino de Bogotá, portador de la tarjeta profesional No.57492, obrando como apoderado de la Sociedad PHARMACIA CORPORATION, según lo acredita el documento de sustitución de poder a mi favor anexo, para dar cumplimiento al requerimiento notificado por fijación en lista el 05 de Agosto de 2005, cuyo término fue prorrogado mediante escrito radicado el 28 de Septiembre de 2005, de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la Comisión de la Comunidad Andina, Artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la SIC, me permito allegar:

1. Copia del examen preliminar efectuado por la IPEA (Forma PCT/IPEA/409), junto con su correspondiente traducción al castellano.
2. Fotocopia autenticada del documento donde consta la cesión del derecho a la Patente otorgado por los inventores al solicitante, debidamente apostillado, junto con su correspondiente traducción al castellano.
3. Forma PCT/IB/306 expedida por la Oficina Internacional del PCT, en relación con el cambio de domicilio del solicitante.
4. Extracto para publicación y Tarjeta de Archivo Temático.

De la señora jefe atentamente,



JUAN PABLO CADENA SARMIENTO

C.C. No. 80.410.337 de Usaquén

Cra 7a. No. 16-56 Piso 9

Bogotá, Noviembre 29, 2005

CHP/MEV/hsr

43A
JPM

1

426
A36

 Industria y Comercio SUPERINTENDENCIA		SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO DIVISION DE NUEVAS CREACIONES EXTRACTO PARA PUBLICACIÓN SOLICITUD DE PATENTE DE INVENCION PCT	
(21) N° de solicitud: 05 058.718		(51) Int Cl:	
22) Fecha de solicitud: 16-06-2005		(71) Solicitante(s) PHARMACIA CORPORATION	
(30) Prioridad	(31) No. Prioridad 60/434,962	(32) Fecha 20-12-2002	(33) País US
		(72) Inventor(es) Cathleen E. Hanau, Serena Marie Marshon, Matthew J. Graneto, Marvin J. Meyers, Shridher G. Hegde, Ingrid P. Buchler, Kun K. Wu, Shuang Liu, Kassoom Nacro	
		(74) Agente: JUAN PABLO CADENA SARMIENTO	
(85)	Fecha inicio fase nacional: 20-07-2005		(87)
(86)	Detos relativos a la presentación de la solicitud PCT Fecha de presentación de la solicitud: 19-12-2003 No. De solicitud PCT/US2003/040932		Publicación internacional Fecha: 15-07-2004 N° publicación: WO 2004/058176 A2
(54) Título: COMPUESTOS DE PIRAZOL ACICLICO PARA LA INHIBICIÓN DE PREOTEÍNA CINASA-2 ACTIVADA POR PROTEÍNA CINASA ACTIVADA POR MITÓGENOS			

Resumen

Se describen compuestos de pirazol aciclico que inhiben la proteina cinasa2 activada por proteina cinasa activada por mitógenos (MK-2). Se describen métodos de preparar tales compuestos, así como un método de usarlos para la inhibición de MK-2, y para la prevención o tratamiento de una enfermedad o trastorno que es mediado por TNF α , donde el método incluye administrar al individuo un compuesto inhibidor de MK-2 de la presente invención. Se describen asimismo composiciones farmacéuticas y estuches que contienen los presentes compuestos inhibidores de MK-2.

3

1/28
437

PATENT COOPERATION TREATY

PCT

REC'D 14 JAN 2005

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

IB/PO

PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 18438/03039		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/ISPA4416)	
International application No. PCT/US03/40392	International filing date (day/month/year) 19 December 2003 (19.12.2003)	Priority date (day/month/year) 20 December 2002 (20.12.2002)	
International Patent Classification (IPC) or national classification and IPC IPC(7): C07D 401/14 and US Cl.: 544/167			
Applicant PHARMACIA CORPORATION			
1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of 4 sheets, including this cover sheet. ☐ This report is also accompanied by ANNEKES, L., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of ___ sheets. 3. This report contains indications relating to the following items: I ☒ Basis of the report II ☐ Priority III ☒ Non-establishment of report with regard to novelty, inventive step and industrial applicability IV ☐ Lack of unity of invention V ☒ Reasoned statement under Article 33(2) with regard to novelty, inventive step or industrial applicability; objections and explanations supporting such statement VI ☐ Certain documents cited VII ☐ Certain defects in the international application VIII ☐ Certain observations on the international application			
Date of submission of the demand 14 June 2004 (14.06.2004)		Date of completion of this report 19 December 2004 (19.12.2004)	
Name and mailing address of the IP/EA/US Mail Stop PCT, Attn: IP/EA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3130		Authorized officer Graham M M Shattuck Telephone No. (571) 272-1630	

Form PCT/ISPA/403 (cover sheet) July 1998

4

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/IB93/4032

I. Basis of the report

1. With regard to the elements of the international application:^a

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-240 _____ as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____
- ☒ the claims:
pages 241-261 _____ as originally filed
pages NONE _____, as amended (together with any statement) under Article 19
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____
- ☒ the drawings:
pages 1-2 _____ as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____
- ☒ the sequence listing part of the description:
pages NONE _____ as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____, which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(h)).
- ☐ the language of publication of the international application (under Rule 48.3(h)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig. NONE

5. ☐ This report has been established as if (none of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).^{a*}

^a Replacements sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

^{a*} Any replacements sheet containing such amendments must be referred to under item I and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/40982

489
439

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
☒ claims Nos. 2-30

because:

- ☐ the said international application, or the said claim Nos. _____ relate to the following subject matter which does not require international preliminary examination (specify):

- ☐ the description, claims or drawings (indicate particular elements below) or said claims Nos. _____ are so unclear that no meaningful opinion could be formed (specify):

- ☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

- ☒ no international search report has been established for said claims Nos. 2-30

2. A meaningful international preliminary examination cannot be carried out due to the failure of the applicant and/or certain and/or sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
☐ the computer readable form has not been furnished or does not comply with the standard.

6

480
440

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/40962

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)

Claims 1 _____ YES
Claims ~~NONE~~ _____ NO

Inventive Step (IS)

Claims 1 _____ YES
Claims ~~NONE~~ _____ NO

Industrial Applicability (IA)

Claims 1 _____ YES
Claims ~~NONE~~ _____ NO

2. CITATIONS AND EXPLANATIONS

The invention relates to certain cyclic and heterocyclic compounds, pharmaceutical compositions comprising such compounds which inhibit mitogen-activated protein kinase-activated protein kinase-2. Considering the prior art cited (US 6,469,028 B1) in the International search report, claim 1 of this invention is novel. The closest prior art of record is US 6,469,028 B1. Claim 1 meets the criteria set out in PCT rule 33(2)-(4), because the prior art do not teach or fairly suggest the compounds which inhibit MEK-2 that are useful in the treatment of TNF-alpha mediated diseases or disorders as described in this application.

X

TRATADO SOBRE COOPERACIÓN INTERNACIONAL
EN MATERIA DE PATENTES

PCT

INFORME DE EXAMEN PRELIMINAR INTERNACIONAL
(Artículo 36 y Regla 70 PCT)

No. de Expediente del Solicitante o Apoderado 18438/09099	PROCEDIMIENTO POSTERIOR Véase comunicación sobre el envío del Informe de examen preliminar internacional (Formulario PCT/IPEA/416)	
No. de Solicitud Internacional PCT/US03/40932	Fecha Internacional de Presentación (día/mes/año) 19 de Diciembre de 2003 (19.12.2003)	Fecha de Prioridad (día/mes/año) 20 de Diciembre de 2002 (20.12.2002)
Clasificación Internacional de Patente (IPC) o Clasificación Nacional e IPC IPC(7): C07D 104/14 y US Cl.: 548/187		
Solicitante PHARMACIA CORPORATION		

1.	Este Informe de examen preliminar internacional fue elaborado por la Oficina Encargada del Examen Preliminar Internacional y se envía al solicitante según Artículo 36.
2.	Este INFORME comprende un total de <u>4</u> hojas, inclusive esta portada ☐ Además se adjuntan ANEXOS al Informe; en este caso se trata de hojas con descripciones, reivindicaciones y/o dibujos, que se modificaron y que sirven de base a este Informe, y/o hojas con correcciones efectuadas por esta oficina (véase Regla 70.16 y Sección 807 de las Instrucciones administrativas al PCT). Estos anexos comprenden en total de _____ hojas.
3.	Este Informe contiene datos con respecto a los siguientes puntos: I ☒ Base del Informe II ☐ Prioridad III ☒ Sin elaboración de un dictamen sobre novedad, actividad inventiva y posibilidad de aplicación Industrial IV ☐ Uniformidad deficiente de la invención V ☒ Declaración justificada según Artículo 35(2) con respecto a la novedad, la actividad inventiva y la posibilidad de aplicación Industrial; documentos y explicaciones que sustentan esta declaración VI ☐ Ciertos documentos enumerados VII ☐ Ciertas deficiencias del registro internacional VIII ☒ Ciertas observaciones relacionadas con la solicitud internacional

Fecha de presentación de la petición 14 de junio de 2004 (14.06.2004)	Fecha de la preparación de este Informe 19 de diciembre de 2004 (19.12.2004)
Nombre y dirección postal de la IPEA/US Parada de Correo PCT, Attn.: IPEA/US Comisionado para patentes Casilla postal 1450 Alexandria, Virginia 22313-1450 Facsimile No.(703) 305-3230	Empleado Autorizado Golam M M Shameen Teléfono No. 571 - 272 - 1600

Formulario PCT/IPEA/409 (hoja de portada)(Julio de 1998)

482
442

INFORME DEL EXAMEN PRELIMINAR INTERNACIONAL

Solicitud Internacional No.
PCT/US03/40832

I. Bases para este informe.

1. Respecto a los elementos de la solicitud internacional:*

- ☒ la solicitud internacional como se entregó originalmente
- ☒ la descripción:
páginas 1-240 como se entregaron originalmente
páginas NINGUNA como se entregaron con la demanda
páginas NINGUNA como se entregaron con la carta de _____
- ☒ las reivindicaciones:
páginas 241-261 como se entregaron originalmente
páginas NINGUNA como se corrigieron (junto con cualquier declaración) bajo el Artículo 19
páginas NINGUNA como se entregaron con la demanda
páginas NINGUNA como se entregaron con la carta de _____
- ☒ los dibujos
páginas 1-2 como se entregaron originalmente
páginas NINGUNA como se entregaron con la demanda
páginas NINGUNA como se entregaron con la carta de _____
- ☒ la lista de la descripción
páginas NINGUNA como se entregaron originalmente
páginas NINGUNA como se entregaron con la demanda
páginas NINGUNA como se entregaron con la carta de _____

2. Respecto al idioma, todos los elementos anteriormente marcados estaban disponibles o fueron suministrados a esta oficina en el idioma en el que se entregó la solicitud internacional, a menos que se diga lo contrario en este punto. Estos elementos estaban disponibles o fueron entregados a esta oficina en el siguiente idioma _____ los cuales son

- ☐ El idioma de la traducción entregada para propósitos de la búsqueda internacional (Regla 23.1 (b)).
- ☐ El idioma de publicación de la solicitud internacional (bajo la Regla 48.3 (b)).
- ☐ El idioma de la traducción entregada para propósitos del examen preliminar internacional (bajo las Reglas 55.2 y/o 55.3)

3. respecto a cualquier secuencia de nucleótido y/o aminoácidos divulgados en esta solicitud internacional, el examen preliminar internacional se realizó sobre la base de la secuencia:

- ☐ contenida en la solicitud en forma impresa
- ☐ entregada junto con la solicitud internacional en una forma legible en un computador
- ☐ suministrada subsiguientemente a esta oficina de forma escrita
- ☐ suministrada subsiguientemente a esta oficina en forma legible en un computador
- ☐ la declaración que la secuencia escrita suministrada no va más allá de lo divulgado en la solicitud internacional como se entregó ha sido suministrada
- ☐ La declaración que la información registrada en la forma legible a computador es idéntica a la secuencia escrita ha sido suministrada.

4. ☒ Las correcciones han resultado en la cancelación de:

- ☒ la descripción, páginas NINGUNA
- ☒ las reivindicaciones, Nos. NINGUNA
- ☒ los dibujos, hojas/figuras NINGUNA

5. ☐ Este informe ha sido admitido como el (algunas de) las enmendaduras no hubieran sido hechas, ya que se considera que estas van más allá de la divulgación preliminar, como se indica el Apartado Suplementario (Regla 70.2 (c)). **

* Las hojas de reemplazo que han sido suministradas a la Oficina receptora en respuesta a una invitación bajo el Artículo 14 se mencionan en este informe como "entregadas originalmente" y no se anexan a este informe ya que no contienen enmendaduras (Reglas 70.16 y 70.17)

** Cualquier hoja de reemplazo que contiene tales enmiendas debe mencionarse bajo el asunto 1 de este informe.

9

433
443

INFORME DEL EXAMEN PRELIMINAR INTERNACIONAL

No. de Solicitud Internacional
PCT/US03/40932

III. Sin establecimiento de una opinión con respecto a la novedad, el nivel inventivo o la aplicabilidad industrial.

1. La pregunta de si la invención reivindicada parece ser nueva, involucra un nivel inventivo o es industrialmente aplicable no ha sido y no será examinada con respecto a:

☐ La totalidad de la solicitud internacional

☒ La(s) reivindicación(es) No. 2 - 30

Porque:

☐ Dicha solicitud internacional, o dichas reivindicaciones No. ____ se relacionan a la siguiente materia la cual no requiere del examen preliminar (*especifique*)

☐ La descripción, las reivindicaciones o los dibujos (*indique a continuación los elementos particulares*) o dichas reivindicaciones No. 2 son tan poco claras que no se puede formar una opinión significativa (*especifique*):

☐ Las reivindicaciones, o dichas reivindicaciones No. ____ están tan inadecuadamente sustentadas por la descripción que no puede formar una opinión significativa

☒ No se ha establecido un informe de búsqueda internacional para dichas reivindicaciones No 2 - 30

2. No se puede llevar a cabo un examen preliminar internacional debido a la falla de la secuencia de nucleótidos y/o aminoácidos de cumplir con el estándar proporcionado en el anexo C de las Instrucciones Administrativas:

☐ No se ha entregado la forma escrita o no cumple con el estándar.

☐ No se ha entregado el forma legible a computador o no cumple con el estándar.

Formulario PCT/IPEA/409 (Apartado III) (Julio 1996)

10

434
44

INFORME DEL EXAMEN PRELIMINAR INTERNACIONAL

No de Solicitud Internacional
PCT/US03/40932

V. Declaración concluyente de acuerdo al Artículo 35(2) respecto a la novedad, el nivel inventivo o la aplicabilidad industrial; citas y explicaciones que soportan tal declaración

1. DECLARACIÓN

Novedad (N)	Reivindicaciones <u>1</u>	Si
	Reivindicaciones <u>NINGUNA</u>	No
Nivel Inventivo (IS)	Reivindicaciones <u>1</u>	Si
	Reivindicaciones <u>NINGUNA</u>	No
Aplicabilidad Industrial (IA)	Reivindicaciones <u>1</u>	Si
	Reivindicaciones <u>NINGUNA</u>	No

2. CITAS Y EXPLICACIONES

La invención se relaciona con ciertos compuestos cíclicos y heterocíclicos, composiciones farmacéuticas que comprendan tales compuestos las cuales inhiben proteína cinasa-2 activada por proteína cinasa activada por mitógeno. Considerando el arte previo citado (US 6.488.028 B1) en el informe de búsqueda internacional, la reivindicación 1 de esta invención es novedosa. El registro de arte previo más cercano es US 6.488.028 B1. La reivindicación 1 cumple los criterios establecidos en el Artículo 33 (2) - (4) del PCT, porque el arte previo no enseña o sugiere compuestos que inhiben MK-2 que son útiles en el tratamiento de enfermedades mediadas por TNF o desórdenes descritos en esta solicitud.

11

ns. 17.002
485
445

Apostille

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America

This public document
2. has been signed by ANITA R. WORTHAM
3. acting in the capacity of NOTARY PUBLIC
4. bears the seal/stamp of ANITA R. WORTHAM-NOTARY PUBLIC-STATE OF MISSOURI

Certified

5. at Jefferson City, Missouri
6. the 25TH day of OCTOBER, 2005
7. by Robin Carnahan, Secretary of State, State of Missouri
8. No. 138903
9. Seal/Stamp
10. Signature:

Robin Carnahan

Comm. 48 (01-2005)



12

STATE OF MISSOURI)
) ss.
COUNTY OF ST. LOUIS)


486
446

I, Anita R. Wortham, a Notary Public in and for said state, do certify that on October 11, 2005, I carefully compared the attached copy of Assignment document, and the original I now hold in my possession as a notarial record. The attached is a complete, full, true and exact copy of the original document.

Anita R. Wortham
Signature of Notary Public

Anita R. Wortham
Printed Name of Notary Public

My Commission Expires: 1-12-08



13



RECEIVED

OCT 25 2004

428
447

UNITED STATES PATENT AND TRADEMARK OFFICE

NELSON MULLINS

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

COLUMBIA OFFICE

OCTOBER 19, 2004

NELSON MULLINS RILEY & SCARBOROUGH
CHARLES E. DUNLAP
P.O. BOX 11070
COLUMBIA, SC 29211-1070

PTAS

RECEIVED

NOV 01 2004

102731364A

ST. LOUIS PATENT OFFICE

?

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/22/2004

REEL/FRAME: 015254/0928
NUMBER OF PAGES: 13

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
HANAU, CATHLEEN E.

DOC DATE: 12/31/2003

ASSIGNOR:
MERSHON, SERENA MARIE

DOC DATE: 01/07/2004

ASSIGNOR:
GRANETO, MATTHEW J.

DOC DATE: 01/05/2004

ASSIGNOR:
MEYERS, MARVIN J.

DOC DATE: 01/05/2004


ASSIGNOR:
HEGDE, SHRIDHAR G.

DOC DATE: 01/05/2004

ASSIGNOR:
BUCHLER, INGRID P.

DOC DATE: 01/07/2004

P.O. Box 1450, Alexandria, Virginia 22313-1450 - www.USPTO.gov



14

488
440

ASSIGNOR:
WU, KUN K.

DOC DATE: 01/07/2004

ASSIGNOR:
LIU, SHUANG

DOC DATE: 12/30/2003

ASSIGNOR:
NACRO, KASSOUM

DOC DATE: 01/06/2004


ASSIGNEE:
PHARMACIA CORPORATION
MAIL ZONE MC5S
575 MARYVILLE CENTRE DRIVE
ST. LOUIS, MISSOURI 63141

SERIAL NUMBER: 10742494 7
PATENT NUMBER:

FILING DATE: 12/19/2003
ISSUE DATE:

TITLE: ACYCLIC PYRAZOLE COMPOUNDS FOR THE INHIBITION OF MITOGEN ACTIVATED
PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2

MARCUS KIRK, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



15



Applicant's Docket No. 18438/09075

04-28-2004



PATENT

489
449

IN THE UNITED STATES PA:

102731364

Mail Stop Assignment Recordation Services
Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

ASSIGNMENT (DOCUMENT) COVER SHEET (37 C.F.R. § 3.31)

Attached please find an assignment (document) for recordal.

IDENTIFICATION OF APPLICATION(S) AND/OR PATENT(S)
FOR ASSIGNMENT (DOCUMENT) RECORDAL
(37 C.F.R. § 3.21 and 37 C.F.R. § 3.31(a)(4))

1. This assignment is for the following patent application and/or issued patent:

- a. Non-Provisional application: SN: 10/742,494, filed on December 19, 2003

TOTAL NUMBER OF APPLICATIONS AND/OR PATENTS
AND TOTAL FEE

2. A. The total number of applications and/or patents identified in this cover sheet is: 1.
B. The total fee is (37 C.F.R. Section 1.21(h)):

$$1 \times \$40.00 = \$40.00$$

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Director of the United States Patent and Trademark Office,
P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

☒ with sufficient postage as first class mail.

37 C.F.R. § 1.10*

☐ as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

☐ facsimile transmitted to the Patent and Trademark Office, (703) _____

Date: 4/20/04

Debra Dun-Brown
Signature

Debra Dun-Brown

(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.



16

C. Payment of fee is made by:

Attached is Check No. 24393 in the amount of \$170.00. This includes a payment of \$130 late fee for filing of Declaration and Power of Attorney

Charge any additional fees required by this paper or credit any overpayment to Deposit Account No. 50-2548.

A duplicate of this paper is attached.

**NAME OF PARTIES CONVEYING INTEREST
(37 C.F.R. § 3.31(a)(1))**

3. The parties conveying interest are:

Cathleen E. Hanau
Serena Marie Mershon
Matthew J. Granelo
Marvin J. Meyers
Shridhar G. Hegde
Ingrid P. Buchler
Kun K. Wu
Shuang Liu
Kassoum Nacro

**NAME AND ADDRESS OF PARTY(IES) RECEIVING INTEREST
(37 C.F.R. § (a)(2))**

4. The rights are being conveyed to:

Pharmacia Corporation
Mail Zone MC5S
575 Maryville Centre Drive
St. Louis, MO 63141

**DESCRIPTION OF INTEREST CONVEYED OR
TRANSACTION RECORDED (37 C.F.R. § 3.31(a)(3))**


5. The accompanying document intends to accomplish an assignment.

**NAME AND ADDRESS OF PARTY TO WHOM
CORRESPONDENCE SHOULD BE MAILED (37 C.F.R. § 3.31 (a)(5))**

6. Please address correspondence to:

Name: Charles E. Dunlap
Address: Nelson Mullins Riley & Scarborough, LLP
P.O. Box 11070
Columbia, SC 29211-1070
Telephone No.: 864-250-2238

Assignment (Document) Cover Sheet--page 2 of 3



17

444
451

DATE ASSIGNMENT (DOCUMENT) EXECUTED
(37 C.F.R. § 3.31(a)(7))

7. The attached assignment (document) was executed by Cathleen E. Hanau on December 31, 2003.
The attached assignment (document) was executed by Serena Marie Marshon on January 7, 2004.
The attached assignment (document) was executed by Matthew J. Graneto on January 5, 2004.
The attached assignment (document) was executed by Marvin J. Meyers on January 5, 2004.
The attached assignment (document) was executed by Shridhar G. Hegde on January 5, 2004.
The attached assignment (document) was executed by Ingrid P. Buchler on January 7, 2004.
The attached assignment (document) was executed by Kun K. Wu on January 7, 2004.
The attached assignment (document) was executed by Shuang Liu on December 30, 2003.
The attached assignment (document) was executed by Kassoum Nacro on January 6, 2004.

LANGUAGE OF ASSIGNMENT (DOCUMENT) TO BE RECORDED

8. The attached document is in the English language.

ORIGINAL DOCUMENT OR TRUE COPY SUBMITTED

9. Submitted herewith is a true copy of the original document, which I certify to be a true copy.

STATEMENT (37 C.F.R. § 3.31(a)(9)) AND
SIGNATURE (37 C.F.R. § 3.31(a)(10))

10. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Date:

April 20, 2004




Signature of Practitioner

Reg. No.: 35,124
Tel. No.: 864-250-2238

Charles E. Dunlap
Nelson Mullins Riley & Scarborough, LLP
P.O. Box 11070
Columbia, SC 29211-1070

TOTAL NUMBER OF PAGES BEING SUBMITTED

11. The total number of pages being submitted, including documents is: 13.



Assignment (Document) Cover Sheet—page 3 of 3

18

218
452

ASSIGNMENT

WHEREAS, I/WE, the undersigned, have made certain invention or inventions which are disclosed in patent application(s) and/or provisional patent application(s) entitled:

ACYCLIC PYRAZOLE COMPOUNDS FOR THE INHIBITION OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2


The specification of which was filed as a Non-Provisional Application on December 19, 2003 and given Serial Number 10/742,494, and having attorney docket number 18438/09075.

WHEREAS, PHARMACIA CORPORATION, having its address at Mail Zone MC5S, 575 Maryville Centre Drive, St. Louis, MO, 63141, U.S.A., a business organized under the laws of the State of Delaware, is desirous of acquiring the entire right, title and interest in and to said invention or inventions and any and all patents to be obtained therefor;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt of which is hereby acknowledged, I/WE do hereby sell, assign and transfer to said PHARMACIA CORPORATION, its successors and assigns, the entire right, title and interest in and to said invention or inventions, in any form or embodiment thereof, and in and to said application(s); and in and to any and all applications filed in any country based thereon, including the right to file application in countries other than the country of priority filing under the provisions of any international convention; also in and to any and all improvements on said invention or inventions now or hereafter made by me/us as employee(s), agent(s) or contractor(s) of said PHARMACIA CORPORATION, also the entire right, title and interest in and to any and all patents, including reissues and extensions thereof, to be obtained in any country upon said invention, inventions or improvements, and any and all continuing applications, including divisional, continuation and continuation-in-part applications, substitute applications, and applications claiming benefit of an earlier filed provisional application, which may be filed upon said invention, inventions or improvements in any country; and

I/WE hereby authorize and request the issuing authority to issue any and all patents on said application or applications to said PHARMACIA CORPORATION, as assignee of the entire interest.

I/WE further agree, without any payment by PHARMACIA CORPORATION, other than in reimbursement of reasonable expenses I may incur, to communicate to said PHARMACIA CORPORATION, its representatives or agents, any facts relating to said invention, inventions or improvements, including evidence for purposes of interference, opposition or other legal proceedings, whenever requested; testify in any interference, opposition or other legal proceedings, whenever requested; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective.



19

IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: Cathleen E. Hanau

Date: 12/31/03

Name: CATHLEEN E. HANAU

Residence: 15551 Wendimill Drive, Chesterfield, MO 63017, U.S.A.



State of Missouri

County of ST. LOUIS

On this 31ST day of December, 2003 before me personally appeared Cathleen E. Hanau, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; In testimony whereof I have hereto set my hand and official seal on the day last above-written.

Martha L. Denay
Notary Public

My Commission expires _____



20

IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: [Signature]

Date: 1-7-04

Name: SERENA MARIE MERSHON

Residence: 303 Spring Street, Bessemer, MI 49911 U.S.A.

State of Michigan

County of Gogebic


On this 7th day of Jan., 2004, before me personally appeared Serena Marie Mershon, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above-written.

Patricia King

Notary Public
PATRICIA KING

My Commission expires

NOTARY PUBLIC GOGEBIC CO., MI
MY COMMISSION EXPIRES 6-15-2007



IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: Matthew J. Graneto

Date: 1/05/04

455

Name: MATTHEW J. GRANETO

Residence: 352 Hartwell Ct., Chesterfield, MO 63017 U.S.A.

State of Missouri


County of St. Louis

On this 5 day of January, 2004, before me personally appeared Matthew J. Graneto, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; In testimony whereof I have hereto set my hand and official seal on the day last above-written.

Beverly Pennington
Notary Public

My Commission expires

BEVERLY PENNINGTON
NOTARY PUBLIC - STATE OF MISSOURI
MY COMMISSION EXPIRES 08/12/2008
ST. CHARLES COUNTY



22

IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: 

Date: 1/5/2004

Name: MARVIN J. MEYERS

Residence: 4006 Summerfield Parkway, St. Charles, MO 63304 U.S.A.

State of Missouri


County of St. Louis

On this 5 day of January 2004 before me personally appeared Marvin J. Meyers, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above-written.


Notary Public

My Commission expires

BEVERLY PENNINGTON
NOTARY PUBLIC - STATE OF MISSOURI
MY COMMISSION EXPIRES 08/18/2005
ST. CHARLES COUNTY





IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: Shri Hegde

Date: 01/05/2004

WA
457

Name: SHRIDHAR G. HEGDE

Residence: 130 Holly Garden Drive, Ballwin, MO 63021 U.S.A.

State of Missouri

County of St Louis

On this 5 day of January 2004, before me personally appeared Shridhar G. Hegde, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above-written.

Beverly Pennington
Notary Public

My Commission expires BEVERLY PENNINGTON
NOTARY PUBLIC - STATE OF MISSOURI
MY COMMISSION EXPIRES 08/12/2008
ST. CHARLES COUNTY



IA

IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: [Signature]

Date: 1/7/2004

Name: INGRID P. BUCHLER

Residence: 7627 Delmar Blvd., Apt. 2, South University City, MO 63130 U.S.A.

State of Missouri

County of St. Louis

On this 16th day of January, 2004 before me personally appeared Ingrid P. Buchler, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above-written.

Beverly Pennington
Notary Public

My Commission expires BEVERLY PENNINGTON
NOTARY PUBLIC - STATE OF MISSOURI
MY COMMISSION EXPIRES 08/18/2006
ST. CHARLES COUNTY



448
450

25

IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: KUN

Date: 1/7/2004

Name: KUN K. WU

2241 LAURENWOOD DR., CHESTERFIELD, MO 63017
Residence: 1101 Olive Lake Drive, St. Louis, MO 63132 U.S.A. (P)

State of Missouri

County of St. Louis

On this 7 day of January, 2004 before me personally appeared Kun K. Wu, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above-written.

Beverly Pennington
Notary Public

My Commission expires BEVERLY PENNINGTON
NOTARY PUBLIC - STATE OF MISSOURI
MY COMMISSION EXPIRES 08/12/2008
ST. CHARLES COUNTY



IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: Shuang Liu

Date: 12-30-03

Name: SHUANG LIU

Residence: 302 Polsinelli Drive, Schenectady, NY 12303 U.S.A.

State of New York


County of Albany

On this 30 day of December, 2003, before me personally appeared Shuang Liu, to me known to be the person who executed the foregoing instrument and acknowledged that he executed the same as his free act and deed; in testimony whereof I have hereto set my hand and official seal on the day last above-written.

Joyce Stevens
Notary Public

My Commission expires October 21, 2006

JOYCE STEVENS
Notary Public, State of New York
No. 6114202212
Qualified in Albany County
Commission Expires Oct. 21, 2006



27

IN TESTIMONY WHEREOF, I have hereto set my hand on the date set after my signature.

Signature: ~~Handwritten signature~~

Date: 01-06-04

Name: KASSOUM
KASSOUM-NACRO

Residence: TENEYCK
106 Tenevck Place, Apt. 10, Guiderland, NY 12084 U.S.A.

State of New York

County of Albany

On this 6th day of January, 2004, before me personally appeared KASSOUM
KASSOUM-NACRO, to me
known to be the person who executed the foregoing instrument and acknowledged that he executed the
same as his free act and deed; In testimony whereof I have hereto set my hand and official seal on the
day last above-written.

Handwritten signature of Notary Public

Notary Public

My Commission expires October 21, 2006

JOYCE STEVENS
Notary Public, State of New York
No. 01HAG02212
Qualified in Albany County
Commission Expires Oct. 21, 2006



Handwritten initials

458
462

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
RD Box 1099
Alexandria, Virginia 22313-1099
www.uspto.gov

APPL NO	FILING OR 371 (a) DATE	ART UNIT	FL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/742,494	12/19/2003	1614	850	18438/09075	2	30	2

CONFIRMATION NO. 6265

Charles E. Dunlap
P.O. Box 11070
Columbia, SC 29211

FILING RECEIPT



0000000012281099

Date Mailed: 04/02/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Cathleen E. Hanau, Chesterfield, MO;
Serena Marie Mershon, Bessemer, MI;
Matthew J. Graneto, Chesterfield, MO;
Marvin J. Meyers, Saint Charles, MO;
Shridhar G. Hegde, Ballwin, MO;
Ingrid P. Buchler, South University City, MO;
Kun K. Wu, St. Louis, MO;
Shuang Liu, Schenectady, NY;
Kassoom Nacro, Guiderland, NY;

Assignment For Published Patent Application

Pharmacia Corporation, St. Louis, MO;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/434,962 12/20/2002

Foreign Applications

If Required, Foreign Filing License Granted: 04/01/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts


Non-Publication Request: No

Early Publication Request: No

MVP

RECEIVED

APR 05 2004

NELSON MULLINS
COLUMBIA OFFICE

29

453
463

Title

Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



30

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

GRYTE, David, M.
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, MO 63105
United States of America

Date of mailing (day/month/year)

13 September 2005 (13.09.2005)

Applicant's or agent's file reference

18438/09099

IMPORTANT NOTIFICATION

International application No.

PCT/US2003/040932

International filing date (day/month/year)

19 December 2003 (19.12.2003)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

PHARMACIA CORPORATION
Mail Zone MC5S
575 Maryville Centre Drive
St. Louis, MO 63141
United States of America

State of Nationality

US

State of Residence

US

Telephone No.

(908) 901-8000

Facsimile No.

(908) 901-8379

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

PHARMACIA CORPORATION
700 Chesterfield Parkway West
Chesterfield, MO 63017-1732
United States of America

State of Nationality

US

State of Residence

US

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☐ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 338.70.80

Authorized officer

Chantal AUMAITRE

Telephone No. (41-22) 338 8888

31

Brigard & Castro
Abogados

Apartado 3892

Cra. 7 16-56
Bogotá - Colombia S.A.

Tel. Conm. 3802200
Tel./Fax: (57.1) 2827976
(57.1) 3802700

E.Mail:bricas@brigardycastro.com.co

As.: 97.382

SEÑORES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES
E. S. D.

Ref.: Expediente No. 05 058.718

HECTOR GOMEZ MEJIA, mayor de edad y vecino de esta ciudad, identificado como aparece al pie de mi firma, en mi calidad de Apoderado General de PHARMACIA CORPORATION, manifiesto por el presente que SUSTITUYO el Poder conferido en el abogado JUAN PABLO CADENA SARMIENTO, también mayor de edad y vecino de esta ciudad, identificado como aparece al pie de su firma, para que actúe ante esa División en las diligencias que se adelantan dentro del expediente de la referencia.

El apoderado sustituto queda ampliamente facultado para intervenir ante esa División; presentar solicitudes, modificaciones, y afectaciones; presentar oposiciones; presentar objeciones; presentar demandas de cancelación; interponer y presentar recursos; pagar; notificarse; desistir; conciliar y transigir; renunciar; sustituir y reasumir este Poder; y en general adelantar todas las actuaciones requeridas para la defensa y efectividad de los intereses de mi representada.

Ruego se le reconozca personería en los términos de esta sustitución.

Respetuosamente,



HECTOR GOMEZ MEJIA
C.C. No. 22.720 de Bogotá
T.P. No. 19.436 del C. S. J.

Acepto,



JUAN PABLO CADENA SARMIENTO
C.C. No. 80.410.337 de Usaquén
T.P. No. 57.492 del C. S. J.

32

ALISTAMIENTO DE PRESENTACION PERSONAL Y
RECONOCIMIENTO LE CONTENIDO Y FLEMA

A anterior escrito dirigido a _____

fue presentado personalmente ante el suscrito
totalmente Cuarenta y Uno de Bogotá por

Hector Gomez Mejia

quien se identificó con la Q. C. 22.720.

de Bogotá y T. P. 19.436

C. J. J. declaró que el contenido

del anterior documento es cierto y que lo firma

que le autoriza sea puesta por él, en consecuencia

se firma en Bogotá, _____

05 ENE 2005

Wesley J. J.



REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

466

Folio 456

2020
Bogotá D.C.,

Doctor(a)
GOMEZ MEJIA HECTOR
Apoderado(a) y/o Representante de
PHARMACIA CORPORATION

REFERENCIA	Radicación No.	05 58718
	Solicitud internacional	US2003/040932
	Fecha inicio fase nacional	21/07/2005
	Trámite	11
	Evento	379
	Actuación	416
	Oficio No.	1146
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase
Dado en Bogotá DC.

28 AGO. 2005

ALIX CARMENIA CESPEDES DE VERGEL
Jefe de la división de Nuevas Creaciones

adpa10